β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson's disease

Science

Volumn 357, Issue 6354, 2017, Pages 891-898

  Mittal, Shuchi ^a,b   Bjørnevik, Kjetil ^c,d   Im, Doo Soon ^e   Flierl, Adrian ^f   Dong, Xianjun ^a,b   Locascio, Joseph J ^a,b   Abo, Kristine M ^a   Long, Elizabeth ^a   Jin, Ming ^a,b   Xu, Bing ^g   Xiang, Yang K ^g   Rochet, Jean Christophe ^h   Engeland, Anders ^c,i   Rizzu, Patrizia ^j   Heutink, Peter ^j   Bartels, Tim ^a,b   Selkoe, Dennis J ^a,b   Caldarone, Barbara J ^b,k   Glicksman, Marcie A ^k   Khurana, Vikram ^a,b,l   Schüle, Birgitt ^a,b,l   Park, David S ^e   Riise, Trond ^c,d   Scherzer, Clemens R ^a,b   more..

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF BERGEN   (Norway)

^d HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF OTTAWA   (Canada)

^f PARKINSON S INSTITUTE   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h PURDUE UNIVERSITY   (United States)

ⁱ NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^j GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^k The Harvard Center for Neurodegeneration & Repair   (United States)

^l HARVARD STEM CELL INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; BETA 2 ADRENERGIC RECEPTOR; CLENBUTEROL; HISTONE H3; LIGAND; LYSINE; MESSENGER RNA; ORCIPRENALINE; PROPRANOLOL; SALBUTAMOL; VALPROIC ACID; BETA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; HISTONE; NEUROPROTECTIVE AGENT; SNCA PROTEIN, HUMAN;

BIOCHEMISTRY; CELLS AND CELL COMPONENTS; CYTOGENETICS; DISEASE TREATMENT; GENE EXPRESSION; LIGAND; MUTATION; NERVOUS SYSTEM DISORDER; PROTEIN; RISK FACTOR;

ALPHA SYNUCLEIN GENE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DOSE INCREASE; ENHANCER REGION; GENE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETIC SCREENING; GENETIC TRANSCRIPTION; HISTONE ACETYLATION; HUMAN; HUMAN CELL; INTRON; MOUSE; MPTP-INDUCED PARKINSONISM; NEUROPROTECTION; NONHUMAN; NORWEGIAN (PEOPLE); PARKINSON DISEASE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; RISK REDUCTION; SUBSTANTIA NIGRA; TRANSCRIPTION REGULATION; ACETYLATION; ANIMAL; DRUG EFFECTS; ETHNOLOGY; GENETICS; METABOLISM; NORWAY; RISK; TUMOR CELL LINE;

MUS;

ACETYLATION; ADRENERGIC BETA-1 RECEPTOR AGONISTS; ADRENERGIC BETA-ANTAGONISTS; ALBUTEROL; ALPHA-SYNUCLEIN; ANIMALS; CELL LINE, TUMOR; ENHANCER ELEMENTS, GENETIC; GENE EXPRESSION REGULATION; HISTONES; HUMANS; LIGANDS; MICE; NEUROPROTECTIVE AGENTS; NORWAY; PARKINSON DISEASE; PROMOTER REGIONS, GENETIC; PROPRANOLOL; RECEPTORS, ADRENERGIC, BETA-2; RISK; SUBSTANTIA NIGRA; TRANSCRIPTION, GENETIC;

EID: 85029541597     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.aaf3934     Document Type: Article

References (35)

1. A. B. Singleton et al, Science 302, 841 (2003).
2. M. Farrer et al., Ann. Neurol. 55, 174-179 (2004).
3. D. W. Miller et al, Neurology 62, 1835-1838 (2004).
4. L. Pihlstrøm, M. Toft, Neurogenetics 12, 283-293 (2011).
5. C. R. Scherzer et al, Proc. Natl. Acad. Sci. U.S.A. 105, 10907-10912 (2008).
6. R. L. Clough, L. Stefanis, FASEB J. 21, 596-607 (2007).
7. A. Jowaed, I. Schmitt, O. Kaut, U. Wüllner, J. Neurosci. 30, 6355-6359 (2010).
8. E. Junn et al., Proc. Natl. Acad. Sci. U.S.A. 106, 13052-13057 (2009).
9. M. Carbone, S. Duty, M. Rattray, BMC Neurosci. 13, 38 (2012).
10. See the supplementary materials.
11. U. Dettmer et al., Nat. Commun. 6, 7314 (2015).
12. L. C. Gleeson, K. J. Ryan, E. W. Griffin, T. J. Connor, A. Harkin, Brain Behav. Immun. 24, 1354-1361 (2010).
13. J. M. O'Donnell, Pharmacol. Biochem. Behav. 58, 813-818 (1997).
14. S. Mu et al., Nat. Med. 17, 573-580 (2011).
15. Y. Leng, D. M. Chuang, J. Neurosci. 26, 7502-7512 (2006).
16. Norwegian Institute of Public Health, The Norwegian Prescription Database; www.norpd.no.
17. G. Alves et al., J. Neurol. Neurosurg. Psychiatry 80, 851-857 (2009).
18. B. Ritz et al., Arch. Neurol. 64, 990-997 (2007).
19. P. Subbarao, P. J. Mandhane, M. R. Sears, CMAJ 181, E181-E190 (2009).
20. M. Lund, BioMed Res. Int. 2015, 835080 (2015).
21. J. W. Langston, P. Ballard, J. W. Tetrud, I. Irwin, Science 219, 979-980 (1983).
22. W. Dauer, S. Przedborski, Neuron 39, 889-909 (2003).
23. R. Betarbet et al., Nat. Neurosci. 3, 1301-1306 (2000).
24. C. M. Tanner et al, Environ. Health Perspect 119, 866-872 (2011).
25. E. Hasegawa et al., Arch. Biochem. Biophys. 337, 69-74 (1997).
26. E. Bezard, S. Dovero, B. Bioulac, C. Gross, Exp. Neurol. 148, 288-292 (1997).
27. C. Y. Chung et al, Science 342, 983-987 (2013).
28. A. Flierl et al., PLOS ONE 9, e112413 (2014).
29. L. J. Hsu et al, Am. J. Pathol. 157, 401-410 (2000).
30. R. Di Maio et al., Sci. Transl. Med. 8, 342ra78 (2016).
31. B. Zheng et al., Sci. Transl. Med. 2, 52ra73 (2010).
32. T. C. Rainbow, B. Parsons, B. B. Wolfe, Proc. Natl. Acad. Sci. U.S.A. 81, 1585-1589 (1984).
33. L. Qian et al., J. Immunol. 186, 4443-4454 (2011).
34. K. G. Ardlie et al, Science 348, 648-660 (2015).
35. I. Dunham et al., Nature 489, 57-74 (2012).